«Previous Article|Table of Contents|Next Article»

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:

2024 01

Page:

159-163

Research Field:

Publishing date:

Info

Title:

Progress of neoadjuvant therapy for locally advanced esophageal squamous cell cancer

Author(s):

ZHU Duojie¹; LI Yumin²

1.Department of Thoracic Surgery,Lanzhou University Second Hospital,Gansu Lanzhou 730000,China£»2.Gansu Provincial Key Laboratory of Digestive System Oncology,Gansu Lanzhou 730030,China.

Keywords:

esophageal squamous cell cancer; locally advanced; neoadjuvant chemoradiotherapy; neoadjuvant chemotherapy; neoadjuvant immunotherapy

PACS:

R735.1

DOI:

10.3969/j.issn.1672-4992.2024.01.030

Abstract:

Esophageal squamous cell carcinoma(ESCC) is one of the most common malignancies worldwide,especially in East Asia.ESCC accounts for more than 90% of esophageal cancer.Currently,esophagectomy following neoadjuvant therapy is the mainstay of treatment for locally advanced ESCC.However,the overall survival rate of patients with locally advanced ESCC is not satisfactory even when treated following the standard treatment guidelines.With neoadjuvant chemoradiotherapy,chemotherapy,or emerging immunotherapy,continuous exploration of efficacy in relation to ESCC is expected to improve overall survival further.Here,we reviewed and summarized current progress of neoadjuvant therapy for locally advanced ESCC.

References:

£Û1£ÝSUNG H,FERLAY J,SIEGEL RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries£ÛJ£Ý.CA Cancer J Clin,2021,71(3):209-249.
£Û2£ÝPENNATHUR A,GIBSON MK,JOBE BA,et al.Oesophageal carcinoma£ÛJ£Ý.Lancet,2013,381(9864):400-412.
£Û3£ÝCUNNINGHAM D,ALLUM WH,STENNING SP,et al.Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer£ÛJ£Ý.N Engl J Med,2006,355(1):11-20.
£Û4£ÝSHAPIRO J,VAN LANSCHOT JJB,HULSHOF MCCM,et al.Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer(CROSS):Long-term results of a randomised controlled trial£ÛJ£Ý.Lancet Oncol,2015,16(9):1090-1098.
£Û5£ÝYANG H,LIU H,CHEN Y,et al.Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus(NEOCRTEC5010):A phase ¢ó multicenter,randomized,open-label clinical trial£ÛJ£Ý.J Clin Oncol,2018,36(27):2796-2803.
£Û6£ÝPUETZ K,BOLLSCHWEILER E,SEMRAU R,et al.Neoadjuvant chemoradiation for patients with advanced oesophageal cancer-which response grading system best impacts prognostic discrimination£ÛJ£Ý.Histopathology,2019,74(5):731-743.
£Û7£ÝMARIETTE C,DAHAN L,MORNEX F,et al.Surgery alone versus chemoradiotherapy followed by surgery for stage ¢ñ and ¢ò esophageal cancer:Final analysis of randomized controlled phase ¢ó trial FFCD 9901£ÛJ£Ý.J Clin Oncol£¬2014,32(23):2416-2422.
£Û8£ÝVALLB¦ZHMER D,H¦ZLSCHER AH,DEMEESTER S,et al.A multicenter study of survival after neoadjuvant radiotherapy/chemotherapy and esophagectomy for ypT0N0M0 R0 esophageal cancer£ÛJ£Ý.Ann Surg,2010,252(5):744-749.
£Û9£ÝHUANG TC,HSU CH,LIN CC,et al.Systematic review and network Meta-analysis:Neoadjuvant chemoradiotherapy for locoregional esophageal cancer£ÛJ£Ý.Jpn J Clin Oncol,2015,45(11):1023-1028.
£Û10£ÝZACHERL J.The current evidence in support of multimodal treatment of locally advanced,potentially resectable esophageal cancer£ÛJ£Ý.Dig Dis,2014,32(1-2):171-175.
£Û11£ÝKRANZFELDER M,SCHUSTER T,GEINITZ H,et al.Meta-analysis of neoadjuvant treatment modalities and definitive non-surgical therapy for oesophageal squamous cell cancer£ÛJ£Ý.Br J Surg,2011,98(6):768-783.
£Û12£ÝDENG HY,WANG WP,WANG YC,et al.Neoadjuvant chemoradiotherapy or chemotherapy? A comprehensive systematic review and Meta-analysis of the options for neoadjuvant therapy for treating oesophageal cancer£ÛJ£Ý.Eur J Cardiothorac Surg,2017,51(3):421-431.
£Û13£ÝVAN HAGEN P,HULSHOF MC,VAN LANSCHOT JJ,et al.Preoperative chemoradiotherapy for esophageal or junctional cancer£ÛJ£Ý.N Engl J Med,2012,366(22):2074-2084.
£Û14£ÝMEREDITH KL,WEBER JM,TURAGA KK,et al.Pathologic response after neoadjuvant therapy is the major determinant of survival in patients with esophageal cancer£ÛJ£Ý.Ann Surg Oncol,2010,17(4):1159-1167.
£Û15£ÝCHAO YK,CHAN SC,LIU YH,et al.Pretreatment T3-4 stage is an adverse prognostic factor in patients with esophageal squamous cell carcinoma who achieve pathological complete response following preoperative chemoradiotherapy£ÛJ£Ý.Ann Surg,2009,249(3):392-396.
£Û16£ÝLENG X,HE W,YANG H,et al.Prognostic impact of postoperative lymph node metastases after neoadjuvant chemoradiotherapy for locally advanced squamous cell carcinoma of esophagus:From the results of NEOCRTEC5010,a randomized multicenter study£ÛJ£Ý.Ann Surg,2021,274(6):e1022-e1029.
£Û17£ÝCHAO YK,CHEN HS,WANG BY,et al.Factors associated with survival in patients with oesophageal cancer who achieve pathological complete response after chemoradiotherapy:A nationwide population-based study£ÛJ£Ý.Eur J Cardiothorac Surg,2017,51(1):155-159.
£Û18£ÝLI H,FANG W,YU Z,et al.Chinese expert consensus on mediastinal lymph node dissection in esophagectomy for esophageal cancer(2017 edition)£ÛJ£Ý.J Thorac Dis,2018,10(4):2481-2489.
£Û19£ÝAJANI JA,D'AMICO TA,BENTREM DJ,et al.Esophageal and esophagogastric junction cancers,version 2.2019,NCCN clinical practice guidelines in oncology£ÛJ£Ý.J Natl Compr Canc Netw,2019,17(7):855-883.
£Û20£ÝSJOQUIST KM,BURMEISTER BH,SMITHERS BM,et al.Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma:An updated Meta-analysis£ÛJ£Ý.Lancet Oncol,2011,12(7):681-692.
£Û21£ÝJapan Esophageal Society.Japanese classification of esophageal cancer,11th edition:Part ¢ñ£ÛJ£Ý.Esophagus£¬2017,14(1):1-36.
£Û22£ÝJapan Esophageal Society.Japanese classification of esophageal cancer,11th edition:Part ¢ò and ¢ó£ÛJ£Ý.Esophagus,2017,14(1):37-65.
£Û23£ÝNAKAYAMA K.Experiences in the treatment of esophageal cancer of the upper and middle thoracic segment£ÛJ£Ý.Surg Annu,1977,9:125-132.
£Û24£ÝAKIYAMA H,TSURUMARU M,UDAGAWA H,et al.Radical lymph node dissection for cancer of the thoracic esophagus£ÛJ£Ý.Ann Surg,1994,220(3):364-373.
£Û25£ÝIIZUKA T,IDE H,KAKEGAWA T,et al.Preoperative radioactive therapy for esophageal carcinoma.Randomized evaluation trial in eight institutions£ÛJ£Ý.Chest,1988,93(5):1054-1058.
£Û26£ÝANDO N,IIZUKA T,IDE H,et al.Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus:A Japan Clinical Oncology Group study¡ªJCOG9204£ÛJ£Ý.J Clin Oncol,2003,21(24):4592-4596.
£Û27£ÝANDO N,KATO H,IGAKI H,et al.A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus(JCOG9907)£ÛJ£Ý.Ann Surg Oncol,2012,19(1):68-74.
£Û28£ÝZHENG Y,LI Y,LIU X,et al.A phase ¢ó,multicenter randomized controlled trial of neoadjuvant chemotherapy paclitaxel plus cisplatin versus surgery alone for stage ¢òa-¢ób esophageal squamous cell carcinoma£ÛJ£Ý.J Thorac Dis,2017,9(1):200-204.
£Û29£ÝKOJIMA T,SHAH MA,MURO K,et al.Randomized phase ¢ó KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer£ÛJ£Ý.J Clin Oncol,2020,38(35):4138-4148.
£Û30£ÝHUANG J,XU J,CHEN Y,et al.Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma(ESCORT):A multicentre,randomised,open-label,phase 3 study£ÛJ£Ý.Lancet Oncol,2020,21(6):832-842.
£Û31£ÝKATO K,CHO BC,TAKAHASHI M,et al.Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy(ATTRACTION-3):A multicentre,randomised,open-label,phase 3 trial£ÛJ£Ý.Lancet Oncol,2019,20(11):1506-1517.
£Û32£ÝSHEN L,KATO K,KIM SB,et al.Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma(RATIONALE-302):A randomized phase ¢ó study£ÛJ£Ý.J Clin Oncol,2022,2022:JCO2101926.
£Û33£ÝSUN JM,SHEN L,SHAH MA,et al.Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer(KEYNOTE-590):A randomised,placebo-controlled,phase 3 study£ÛJ£Ý.Lancet,2021,398(10302):759-771.
£Û34£ÝLUO H,LU J,BAI Y,et al.Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma:The ESCORT-1st randomized clinical trial£ÛJ£Ý.JAMA,2021,326(10):916-925.
£Û35£ÝLI HC,ZHAO S,ZHENG Y,et al.Preoperative pembrolizumab combined with chemoradiotherapy for oesophageal squamous cell carcinoma(PALACE-1)£ÛJ£Ý.Eur J Cancer,2021,144:232-241.
£Û36£ÝLIU J,YANG Y,LIU Z,et al.Multicenter,single-arm,phase ¢ò trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma£ÛJ£Ý.J Immunother Cancer,2022,10(3):e004291.

Memo

Memo:

2021Äê¤ԭÇàÄ괴д´ÒµÈ˲ţ¨ÍŶӣ©ÏîÄ¿£¨±àºÅ£º2021LQTD11£©

Common functions

Last Update: 2023-11-30